173 related articles for article (PubMed ID: 38186978)
1. Combinational use of trabectedin and pegylated liposomal doxorubicin for recurrent ovarian cancer: a meta-analysis of phase III randomized controlled trials.
Li C; Qiao S; Kang M; Gao X; Li Z
Am J Transl Res; 2023; 15(12):6675-6689. PubMed ID: 38186978
[TBL] [Abstract][Full Text] [Related]
2. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Lawrie TA; Bryant A; Cameron A; Gray E; Morrison J
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006910. PubMed ID: 23835762
[TBL] [Abstract][Full Text] [Related]
3. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
[TBL] [Abstract][Full Text] [Related]
4. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
[TBL] [Abstract][Full Text] [Related]
5. A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.
Pignata S; Scambia G; Villanucci A; Naglieri E; Ibarbia MA; Brusa F; Bourgeois H; Sorio R; Casado A; Reichert D; Dopchie C; De Rivas B; de Sande LM
Oncologist; 2021 Apr; 26(4):e658-e668. PubMed ID: 33289956
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Park YC; Parekh TV; Poveda AM
Eur J Cancer; 2012 Oct; 48(15):2361-8. PubMed ID: 22541893
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
Poveda A; Vergote I; Tjulandin S; Kong B; Roy M; Chan S; Filipczyk-Cisarz E; Hagberg H; Kaye SB; Colombo N; Lebedinsky C; Parekh T; Gómez J; Park YC; Alfaro V; Monk BJ
Ann Oncol; 2011 Jan; 22(1):39-48. PubMed ID: 20643862
[TBL] [Abstract][Full Text] [Related]
8. The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials.
Li XR; Zhu Y; Zhang GN; Huang JM; Pei LX
J Ovarian Res; 2021 Mar; 14(1):42. PubMed ID: 33750444
[TBL] [Abstract][Full Text] [Related]
9. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Lisyanskaya AS; Makhson AN; Rolski J; Gorbounova VA; Ghatage P; Bidzinski M; Shen K; Ngan HY; Vergote IB; Nam JH; Park YC; Lebedinsky CA; Poveda AM
J Clin Oncol; 2010 Jul; 28(19):3107-14. PubMed ID: 20516432
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.
Sehouli J; Alfaro V; González-Martín A
Ann Oncol; 2012 Mar; 23(3):556-562. PubMed ID: 21734221
[TBL] [Abstract][Full Text] [Related]
11. Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient.
Colombo N
EJC Suppl; 2014 Dec; 12(2):7-12. PubMed ID: 26759526
[TBL] [Abstract][Full Text] [Related]
12. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
13. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
Lawrie TA; Rabbie R; Thoma C; Morrison J
Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010482. PubMed ID: 24142521
[TBL] [Abstract][Full Text] [Related]
14. Real-world experience with trabectedin for the treatment of recurrent ovarian cancer.
Romero I; López-Guerrero JA; Pignata S
Expert Rev Anticancer Ther; 2021 Oct; 21(10):1089-1095. PubMed ID: 34128757
[No Abstract] [Full Text] [Related]
15. The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials.
Gibson JM; Alzghari S; Ahn C; Trantham H; La-Beck NM
Oncologist; 2013; 18(9):1022-31. PubMed ID: 23881990
[TBL] [Abstract][Full Text] [Related]
16. INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Colombo N; Gadducci A; Sehouli J; Rulli E; Mäenpää J; Sessa C; Montes A; Ottevanger NB; Berger R; Vergote I; D'Incalci M; Churruca Galaz C; Chekerov R; Nyvang GB; Riniker S; Herbertson R; Fossati R; Barretina-Ginesta MP; Deryal M; Mirza MR; Biagioli E; Iglesias M; Funari G; Romeo M; Tasca G; Pardo B; Tognon G; Rubio-Pérez MJ; DeCensi A; De Giorgi U; Zola P; Benedetti Panici P; Aglietta M; Arcangeli V; Zamagni C; Bologna A; Westermann A; Heinzelmann-Schwarz V; Tsibulak I; Wimberger P; Poveda A;
Br J Cancer; 2023 Apr; 128(8):1503-1513. PubMed ID: 36759720
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.
Marth C
Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):19-22. PubMed ID: 30223697
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis.
Liu Y; Huang Y; Li J; Wan S; Jiang N; Yang J; Chiampanichayakul S; Tima S; Anuchapreeda S; Wu J
Front Pharmacol; 2022; 13():1010626. PubMed ID: 36438821
[No Abstract] [Full Text] [Related]
19. GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.
Selle F; Heudel PE; Hardy-Bessard AC; Pozet A; Meunier J; Gladieff L; Lotz JP; Provansal M; Augereau P; Berton D; Bonichon-Lamichhane N; Orfeuvre H; Pautier P; Kalbacher E; Tazi Y; Spaeth D
Anticancer Res; 2020 Jul; 40(7):3939-3945. PubMed ID: 32620635
[TBL] [Abstract][Full Text] [Related]
20. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
Romero I; Mallol P; Santaballa A; Del Campo JM; Mori M; González-Santiago S; Casado A; Vicente D; Ortega E; Herrero A; Guerra E; Barretina-Ginesta P; Rubio MJ; Martínez A; Bover I; Vidal L; Arcusa Á; Martín L; García Y; González-Martín A
Anticancer Drugs; 2019 Jul; 30(6):628-635. PubMed ID: 31008727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
